Introduction and Objective: Efforts to improve influenza vaccination rates among patients with diabetes can be enhanced with accurate documentation of vaccination status in the electronic medical record (EMR). This quality improvement project aimed to identify factors contributing to inaccurate vaccination status in the EMR documentation.Methods: Ambulatory patients with diabetes presenting for routine follow up were […]
Read MoreMonth: July 2025
2160-LB: Long-Acting Exendin 4 Protein Enhances Insulin Secretion and Improves Steatotic Liver in High-Fat Diet–Fed Mice
Introduction and Objective: Exendin-4 (Ex-4) is a glucagon-like peptide-1 receptor agonist used for the treatment of type 2 diabetes and other metabolic disorders, including steatotic liver disease. However, its short half-life necessitates multiple daily injections, resulting in poor patient compliance, limited efficacy, and increased treatment costs. To address this problem, we introduce a novel drug […]
Read More466-P: Exploration of Single Nucleotide Polymorphisms Associated with Small-Fiber Neuropathy
Introduction and Objective: Introduction & Objective: Small fiber neuropathy (SFN) is known to develop early in the course of diabetic polyneuropathy (DPN). It has been shown that single nucleotide polymorphisms (SNPs) are involved in DPN, but how SNPs correlate with SFN has not yet been investigated. In the present study, we explored the correlation in […]
Read More215-OR: Increased White Adipose Tissue Oxidative Capacity and Insulin Resistance Are Early Changes upon High-Fat Diet in Healthy Humans
Introduction and Objective: Hypercaloric nutrition may sequentially promote insulin resistance across tissues. Recent rodent studies indicate white adipose tissue (WAT) as key driver of whole-body insulin resistance. Thus, we hypothesized that WAT may respond early to overnutrition-induced metabolic changes in humans.Methods: In a randomized, parallel-group study, young glucose tolerant volunteers consumed either an isocaloric (ID; […]
Read More105-OR: ADA Presidents' Select Abstract: Enhanced Dopamine and Opioid Receptor Target Engagement Predicts Neuropathic Pain Treatment Response—A Resting-State fMRI Study in Painful Diabetic Neuropathy
Introduction and Objective: Painful diabetic neuropathy (DN) is a common and challenging complication of diabetes with limited treatments. Our research reveals that treatment responders show enhanced connectivity between the insula and corticolimbic systems, modulated by dopamine and opioid receptors. These findings highlight potential mechanisms of treatment efficacy and pathways for novel therapeutic development.Methods: 43 participants […]
Read More2159-LB: Hepatic PAQR4 Contributes to Metabolic Regulation by Mediating Ceramide Levels and Hepatokine Signaling
Introduction and Objective: PAQR4, an orphan receptor within the progestin and adipoQ receptor family (PAQR1-11), is implicated in multiple cancers, including hepatocellular carcinoma (HCC). However, its metabolic function in hepatocytes remains unclear. Our recent findings identify PAQR4 as a key regulator of ceramide metabolism. In adipocytes, PAQR4 overactivation leads to ceramide accumulation, disrupting adipose tissue […]
Read More1006-P: Developing CGMap—Characterizing Continuous Glucose Monitoring Data in Patients with Type 2 Diabetes
Introduction and Objective: To characterize continuous glucose monitoring (CGM) data in patients with type 2 diabetes (T2D), and to assess the relationship between CGM-derived indicators and diabetes-related clinical parameters.Methods: The data was collected from a randomized trial in China (ChiCTR2000039424), in which patients with T2D wore CGM and received acarbose or sitagliptin. Ordinary least square […]
Read More2158-LB: Additive Hepatoprotective Effects of DA-1241, a GPR119 Agonist, in Combination with Efruxifermin in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH
Introduction and Objective: DA-1241, a novel G protein-coupled receptor 119 agonist, recently completed a Phase 2a clinical trial in presumed metabolic dysfunction-associated steatohepatitis (MASH) patients. This study extended previous findings on its hepatoprotective synergy with glucagon-like peptide-1-based drugs and evaluated its anti-MASH effects in combination with a fibroblast growth factor 21 analogue.Methods: Male C57BL/6JRj mice […]
Read More22-OR: Type 2 Diabetes Subtypes and Risk of Dementia in the United States
Introduction and Objective: Dementia, an emerging complication of type 2 diabetes (T2D), may be driven by chronic hyperglycemia and insulin resistance. We evaluated the risk of dementia across T2D subtypes, which differ in clinical profiles and risk of vascular complications.Methods: We identified newly diagnosed T2D (n = 727,076; age: 64.4 years [SD:13.3], 52% female) over […]
Read More2157-LB: The Metabolic Impact of Weight Cycling on Normal Weight Mice and Exploration of Its Mechanisms
Introduction and Objective: An increasing number of individuals with normal weight are attempting weight loss through caloric restriction. However, most weight loss attempts are followed by weight regain, leading to weight cycling. Whether weight cycling poses metabolic risks, especially in normal-weight individuals, remains debated. This study aims to evaluate the effects of weight cycling on […]
Read More